Decide on enrollment expansion for the ADHERE trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- February 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Decision whether to expand enrollment up to 130-140 patients expected in first quarter of 2021”
What we found
Evidence strength A What the grades mean
The company announced a "go" decision in February 2021 to proceed with the second stage of the ADHERE trial, which includes enrolling approximately 130 patients, fulfilling the commitment made for the first quarter of 2021.
-
A Argenx SE 20-F filed 2022-03-21
“In February 2021, we announced a “go” decision to transition into the second, placebo controlled stage of this trial based on a planned efficacy and safety assessment following the enrollment of 30 patients into the initial part of the ADHERE trial.” ✓ confirmed on the page
-
A Argenx SE 20-F filed 2022-03-21
“The ADHERE trial is expected to enroll approximately 130 patients in total to support potential registration of SC efgartigimod for the treatment of CIDP.” ✓ confirmed on the page
Market reaction: the shares moved +1.2% against the S&P 500 over the three sessions around the disclosure (18 Mar 2022 to 23 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Decide
- Deliverable
- ADHERE trial enrollment decision
- Target
- 140 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Argenx SE? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ARGX-021359 · Corrections policy